Galantamine beyond Alzheimer's disease-a fact or artefact?
Affiliations
Affiliations
- Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Shuwaikh, State of Kuwait.
- Pharmacy Department, Kuwait Centre for Mental Health (KCMH), Jamal Abdul-Nassir St., Shuwaikh, State of Kuwait.
Abstract
Galantamine is US-Food and Drug Administration FDA-approved for mild-to-moderate Alzheimer's disease. However, its unique pharmacological portfolio speaks to the idea of a pluripotent agent with a broad therapeutic potential. Here, authors briefly discuss these off-label clinical indications synthesizing the extant evidence.
Keywords: Clinical uses; galantamine; pharmacology.
Similar articles
Update on Alzheimer drugs (galantamine).
Raskind MA.Neurologist. 2003 Sep;9(5):235-40. doi: 10.1097/01.nrl.0000087722.46430.c4.PMID: 12971834 Review.
Galantamine in Alzheimer's disease.
Razay G, Wilcock GK.Expert Rev Neurother. 2008 Jan;8(1):9-17. doi: 10.1586/14737175.8.1.9.PMID: 18088197 Review.
[Galantamine: a novel cholinergic agent for Alzheimer's disease].
Olazarán J, García G.Neurologia. 2002 Oct;17(8):429-36.PMID: 12396973 Spanish.
Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J.Drugs Aging. 2004;21(7):453-78. doi: 10.2165/00002512-200421070-00004.PMID: 15132713 Review.
Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease.
Seltzer B.Clin Interv Aging. 2010 Feb 2;5:1-6.PMID: 20169037 Free PMC article. Review.